

Azadeh Stark PhD, M.Ed.
Curriculum Vitae

Work: 800 W Campbell Rd, Hoblitzelle Hall | 2.118 |
University of Texas in Dallas, Richardson, TX 75080
Azadeh.Stark@utdallas.edu

Work: 2799 West Grand Blvd, Department of Pathology | K-6 |
Henry Ford Health System, Detroit, MI 48202
Astark1@hfhs.org

EDUCATION & ACADEMIC TRAINING

1995-1997	Lineberger Comprehensive Cancer Center University of North Carolina in Chapel Hill	Post-Doctoral Research Fellow Molecular Epidemiology & Pathology
1989-1994	Arizona Comprehensive Cancer Center University of Arizona in Tucson	Ph.D. Nutritional/Molecular Epidemiology
1984-1986	The University of Texas at Austin	M.Ed. International Health
1980-1984	The University of Texas at Austin	B.S. Nutritional Sciences
1980-1984	The University of Texas at Austin	B.A. Biological Sciences

ADDITIONAL EDUCATION & TRAINING

2014	Leadership Development Program Center for Creative Leadership, A US-based International Organization
2008	Management & Leadership Judge School of Business & Management, University of Cambridge, England
2006	Deming Immersion Program Deming Institute, Fordham School of Business, New York
2005	Multi-Level Modeling, Applied Biostatistics Ohio State University Summer Program, Columbus Ohio
2002	Genetic Basis of Human Diseases Jackson Laboratory Summer Program, Bar Harbor, Maine
1996-1997	Kennan-Flagler School of Business, University of North Carolina in Chapel Hill Organizational Behavior & Management
1993	Histopathology of Cancer National Cancer Institute Summer Program, Keystone, Colorado
1986-1987	School of Public Health Public Health Nutrition University of North Carolina in Chapel Hill

PUBLICATIONS (SELECTED)

Azadeh Stark, Matthew Burke, S David Nathanson, Lisa A Newman, Richard J Zarbo, Max Wicha, and Dhanajay Chitale. Current Guidelines for Genetic Testing Under-Represent the Burden of Breast Cancer in Younger Women. Archives of Pathology and Laboratory Medicine (Submitted)

Jigge E, Oppong JK, Bensenhaver J, Aitpillah F, Gyan K, Ishmael K, Osei-Bonsu E, Adjei E, Ohene-Yeboah M, Kathy T, Akpaloo M, Acheampong D, Antwi B, Agyeman FO, Alhassan Z, Fondjo LA, Owusu-Afriyie O, Brewer RN, Johnson T, Wicha M, Merjver S, Kleer C, Amankwaa-Frempong E, **Stark A**, Abantanga F, Newman L, and Awauh B. Breast Cancer in Ghana: Report from the Ten Year Anniversary of the Komfo Anokye Teaching Hospital-University of Michigan Research Partnership. Ghana Medical Journal (Accepted)

Wienmann S, Williams AE, Kamineni A, Buist DSM, Masterson EE, Stout NK, **Stark A**, Ross TR, Ownes CL, Field TS, and Doubeni CA. Cervical cancer screening and follow-up in four geographically diverse U.S. healthcare systems between 1998 and 2007. Cancer 2015; May 18. doi: 10.1002/cncr.29445

Madrid FF, Maroun M-C, Olivero O, Long M, **Stark A**, Grossman LI, Binder W, Dong J, Burke M, Nathanson SD, Zarbo R, Chitale D, Zeballos-Chávez R, Peebles C. Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis. BMC Cancer 2015; 15:407; doi:10.1186/s12885-015-1385-8

Carolyn M Rutter, Bob Greenlee, Eric Johnson, **Azadeh Stark**, Sheila Weinmann, Aruna Kamineni, Kenneth Adams, Diana Buist, and Chyke Doubeni. Prevalence of Colonoscopy before Age 50. Journal of Preventive Medicine 2015; 72:126-129

Maroun MC, Olivero O, Lipovich L, **Stark A**, Tait L, Bandyopadhyay S, Burke M, Zarbo R, Chitale D, Nathanson DS, Long M, Peebles C and Fernandez-Madrid F. Anti-centrosome antibodies in breast cancer are the expression of autoimmunity. Immunol. Res 2014; 60:339-347.

Owen C, Kamineni A, Buist DS, Weinmann S, Ross TR, Willimas AE, **Stark A**, Field TS. Follow-Up and Clinical Significance of Unsatisfactory Liquid-base Pap Tests. Cancer Cytopathology 2014 Oct 23. doi: 10.1002/cncy.21490

J Patricia Dhar, Phillip Levy, Joel Ager, Lisa Chiodo, Daniel Schultz, **Azadeh Stark**, Ann Schwartz, and Robert J Sokol. Premature Cardiovascular Disease in Women with Lupus and Relationship to Disease Severity. Current Women Health Review 2014; 10:226-229

Dhar JP, Gregoire L, Lancaster W, **Stark A**, Essenmacher L, Schultz D, Ager J, Chiodo L, Schwartz AG, Husain M, and Sokol RJ. Evaluation of high risk HPV (HPV-16 and HPV-18) RNA and integration in cervical neoplasms in systemic lupus erythematosus; Current Women's Health Reviews 2014; 9: 189-193

Yan X, Barnholtz-Sloan J Chu C, Colonie R, Webster J, Li L, Prichard J, and **Stark A**. Adiposity, Inflammation, Genetic Variants and Risk of Post-Menopausal Breast Cancer: Findings from a Prospective-specimen-collection, Retrospective-Blinded-Evaluation (PROBE) Design Approach. Breast Cancer Series, SpringerPlus 2013; 2:638-649

Owens CL, Peterson D, Kamineni A, Buist DS, Weinmann S, Ross TR, Williams AE, **Stark A**, Adams KF, and Field TS. Effects of Transitioning from Conventional Methods to Liquid Based Methods on Unsatisfactory Pap Tests: Results from a Multi-Center U.S. Study. Cancer Cytopathology 2013; 121:568-575

Mazor M K, Gaglio B, Nekhlyudov L, Alexander G, **Stark A**, Hornbrook M, Walsh K, Boggs J, Lemay CA, Firreno C, Biggins C, Blosky MA, Arora NK. Assessing Patient-Centered Communication in Cancer Care: Stakeholders Perspective; Journal of Oncology Practice 2013; 9: 186-193

Dillard AJ, Scherer L, Ubel PA, Smith DM, Zikmund-Fisher BJ, McClure JB, Greene S, **Stark A**, Fagerlin A. Breast Cancer Anxiety's Association with Responses to a Chemoprevention Decision Aid. Social Science Medicine 2013; 77:13-19

Josephine P Dhar, Lucie Gregoire, Wayne Lancaster, **Azadeh Stark**, Ann G Schwartz, Daniel Shultz, Lynnette Essenmacher, Joel Ager, Lisa Chiodi, Mujitaba Husain, and Robert J Sokol. Risk for Cervical Intraepithelial Neoplasia in Systemic Lupus Erythematosus is not related to Disease Severity. Current Rheumatology Reviews, 2013; 9:301-304

Theresa Schwartz, **Azadeh Stark**, Judy Pang, Baffour Awuah, Celina Kleer, Solomon Quayson, Stephanie Kingman, Fracis Aitpillah, Francis Abantanga, Evelyn Jiagge, Joseph K Oppong, Ernest Qesi-Bonsu, Iman Martin, Xiaowei Yan, Kathy Toy, Ernest Adjei, Max Wicha, Lisa A Newman. Expression of ALDH1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. Cancer 2013; 119:488-94

Melisa S. Stahl, Jeffery Prichard, and **Azadeh Stark**. Adiposity and risk of proliferative diseases of the breast prior to the diagnosis of invasive breast cancer: A case series pilot study. The Breast Journal 2012; 18 191-194.

Azadeh Stark, Robert Stapp, Aditya Raghunathan, Xiaowei Yan, H. Lester Kirchner, Jennifer Griggs, Lisa Newman, Dhananjay Chitale, and Andrew Dick. Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women. Journal of Breast Cancer Research and Treatment 2012; 131:561-570

Sandra C Hayes, Rebecca Speck, Elizabeth Reimert, **Azadeh Stark**, and Kathryn Schmitz, Does the effect of weight lifting on lymphadema following breast cancer differ by diagnostic method: results from a randomized controlled trial. Journal of Breast Cancer Research and Treatment 2011; 13:227-234.

Andrew Dick, Melony S. Sorbero, James Hayman, Heather T. Gold, Linda Schiffhauer, **Azadeh Stark** and Jennifer J. Griggs. Comparative Effectiveness of the Management of Ductal Carcinoma *in Situ* and the Roles of Margins and Surgeons. Journal of National Cancer Institute 2011; 103:92-104.

Azadeh Stark, Celina Kleer, Iman Martin, Awuah Baffour, Anthony Nsieah, Valerie Takyi, Richard Zarbo, Max Wicha and Lisa Newman. African Ancestry and Triple Negative Cancer. Cancer 2010; 116:4926-4932.

Azadeh Stark, Melissa Stahl, Lester Kirchner, Susan Krum, Jeffrey Prichard and James Evans. Body mass index at the time of diagnosis and the risk of advanced stages and poorly differentiated cancers of the breast: findings from a case-series study. International Journal of Obesity 2010; 34:1381-1386

Peter A. Ubel, Dylan M. Smith, Brian J. Zikmund-Fisher, Holly A. Derry, Jennifer McClure, **Azadeh Stark**, Cheryl Weise, Sarah Greene, Aleksandra Jankovic, and Angela Fagerlin. Testing whether decision aids introduce cognitive biases: Results of a randomized trial. Journal of Patient Education and Counseling 2010;80:158-162

Angela Fagerlin, Sarah Greene, Jennifer McClure, Cheryl Weise, **Azadeh Stark**, Sharon Alford, Brian Zikmund-Fisher, Rosemarie Pitsch, Karin Johnson, Sanja Jankovic, Dylan Smith, Holly Derry, and Peter Ubel. Women's decisions regarding tamoxifen for breast cancer prevention: Responses to a tailored decision aid. *Journal of Breast Cancer Research and Treatment* 2010; 119:613-620

Griggs JJ, Sorbero MS, Ahrendt GM, **Stark A**, Heininger S, Gold HT, Schiffhauer LM, Dick AW. The pen and the scalpel: Effect of diffusion of information on non-clinical variations in surgical treatment. *Medical Care* 2009; 47:749-757

Stark A, Schultz D, Kapke A, Nadkarni P, Linden M and Raju U. Obesity and the risk of less commonly diagnosed subtypes of breast cancer. *Journal of European Surgical Oncology* 2009; 35:928-935

Brian J. Zikmund-Fisher, Peter A. Ubel, Dylan M. Smith, Holly A. Derry, Jennifer B. McClure, **Azadeh Stark**, Rosemarie K. Pitsch, and Angela Fagerlin. Communicating side effect risks in a Tamoxifen prophylaxis decision aid: The de-biasing influence of pictographs. *Journal of Patient Education and Counseling* 2008; 73:209-214

Stark A, Gregoire L, Pilarski R, Zarbo A, Gaba A and Lancaster WD. Human Papilloma Virus, cervical cancer risk factors and women's knowledge. *Journal of Cancer Prevention & Detection* 2008; 32:15-22

Punia J, Klimowicz T, Davis S, and **Stark, A**. Rejected and Unsatisfactory Specimens: A comparative study of Liquid-Based and Conventional methods screening. *Journal of Lab Medicine, A publication of the American Society for Clinical Pathology* 2007; 38:729-733

Stark A, Kapke A, Schultz D, Brown R, Linden M, and Raju U. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: Findings from a prospective cohort study of African-American and White-American women. *Journal of Breast Cancer Research and Treatment* 2007; 107:405-414

Stark A, Jones BA, Chapman D, Wells K, Krajenta R, Meier F and Zarbo RJ. Clinical laboratory specimen rejection: Association with the site of patient care characteristics and time of collection. Findings from a single health care organization. *Journal of Archives of Pathology and Laboratory Medicine* 2007; 131:588-592

Stark A and Schultz D. Accelerated telomere shortening in glycosyl-phosphatidyl-inositol (GPI)-negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH. *Blood* 2006; 108:3620.

Robert W. Carlson, MD; Susan J. Moench, PhD; M. Elizabeth H. Hammond, MD; Edith A. Perez, MD; Harold J. Burstein, MD, PhD; D. Craig Allred, MD; Charles L. Vogel, MD; Lori J. Goldstein, MD; George Somlo, MD; William J. Gradishar, MD; Clifford A. Hudis, MD; Mohammad Jahanzeb, MD; **Azadeh Stark, PhD**; Antonio C. Wolff, MD; Michael F. Press, MD, PhD; Eric P. Winer, MD; Soonmyung Paik, MD; and Britt-Marie Ljung, MD. HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations, 2006

Coon SW, **Stark A**, Peterson EL, Gloi A, Kortsha G, Pounds JG, Chettle DR, and Gorell JM. Whole-body lifetime occupational lead exposure and risk of Parkinson's disease. *Journal of Environmental Health Prospective* 2006; 114:1872-1876

Savera AT, Kaul S, Badani K, **Stark A**, Shah NL, and Menon M. Robotic radical prostatectomy with the “Veil Aphrodita” technique: Histologic evidence of enhanced nerve sparing. *Journal of European Urology* 2006; 49:1065-1074

Stark A, Claud S, Lu M, Kapke, A, Linden M and Griggs J. Race modifies the association between breast cancer pathology prognostic indicators and the positive status for HER-2/*neu*. *Cancer* 2005; 104:2189-2195

Aamodt RL, Anouna A, Baird P, Beck JC, Bledsoe MJ, De Souza Y, Grizzle WE, Gosh J, Holland NT, Hakimian R, Michels C, Pitt KE, Sexton KC, Shea K, **Stark A**, and Vaught J. Best Practices for Repositories I: Collection, storage, and retrieval of human biological materials for research. *Cell Preservation Technology* 2005; 3:5-45

Stark A, Lu M, Mackowiak P, and Linden M. Concordance of the hormone receptors and correlation of the HER-2/*neu* over expression of the meta-chronous cancers of contra-lateral breasts. *The Breast J* 2005; 11:183-187

Stark A, Kucera G, Lu M, Claud S, and Griggs J. Influence of health insurance status on inclusion of HER-2/*neu* testing in the diagnostic workup of breast cancer patients. *Int J for Quality for Health Care* 2004; 16:517-521

Griggs JJ, Sorbero ME, **Stark A**, Heininger SE and Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. *Breast Cancer Research & Treatment* 2003; 81:21-31

Stark A, Prince A, Kucera G, Lu M, Raju U, and Nathanson D. Evaluating post-treatment screening in women with breast cancer. *Cancer Practice* 2002; 10:228-233

Stark A. A historical review of the Harvard and the National Cancer Institute food frequency questionnaires: their similarities, differences, and limitations in assessment of food intake. *Ecology of Food and Nutrition* 2002; 40:1-40

Stark A, Hulka B, Joens S, Novotny D, Wald L, Liu E, and Conway K. HER-2/*neu* amplification in benign breast disease and the risk of subsequent breast cancer. *J Clinical Oncology*, 2000, 18: 267-270

Stark A and Sherman M.D., Factitious diseases of periocular and facial skin. *Am Journal of Ophthalmology* 1999; 128: 392

Stark A and Sherman M.D. Risk factors for constant severe trachoma among preschool children in Kongwa, Tanzania. *Am J Epidemiology* 1997; 3: 285

Hulka BS and **Stark A**. Breast cancer: Cause and prevention. *Lancet* 1995; 346:883-7